Home / Healthcare / Host Cell Contaminant Testing Market

Host Cell Contaminant Testing Market Size, Share & Industry Analysis By Type (Microbial, Mammalian, Others), By Test (PCR, Immunoassay, Others), By End-Users (Pharmaceutical & Biotechnology Industries, Academic & Research Institutes, Diagnostic Centres, Others) and Regional Forecast, 2024-2032

Report Format: PDF | Published Date: Ongoing | Report ID: FBI103115 | Status : Upcoming

Biopharmaceutical companies manufactures and extracts biological products from cell lines. These drugs include vaccines, cell therapies, recombinant protein etc. Biologics are derived from living sources like bacteria, yeasts, fungal, animal or even human by cell culture approach. Biologics can contain polypeptides, sugars, proteins, DNA, RNA, or complex combinations of these substances, or maybe living cells. But this process extraction requires high technical expertise and this process is quite prone to contamination by undesired materials like cellular DNA, RNA, proteins, and microbial contamination which may be antigenic. The global demand for the host cell contaminant testing market has been rising due to the developments in the field of biopharmaceuticals and stringent regulatory requirements for purity of the products.


Factors such as escalation in incidences and the prevalence of cancer and increasing research and development (R&D) activities have increased the focus towards developing biopharmaceutical products driving the market growth. According to the International Agency for Research on Cancer 2018, cancer burden raised to 18.1 million new cases and 9.6 million cancer deaths in 2018. Apart from this, the growing use of biopharmaceutical products in clinical trials, diagnostics are likely to propel the market growth. The overall host cell contaminant testing market is expected to witness significant growth during the forecast period due to factors such as increased cancer research activities, demand for innovative and personalized medicines and other industrial needs like diagnostics.


However, the techniques involved in host cell contaminant testing demands technical expertise which may put high cost and technical barriers in due course that may obstruct the market



Market Segmentation:


The global host cell contaminant testing market can be segmented on the basis of the product type, test, end-users, and region. Based on the type, the market can be segmented into microbial, mammalian, and others. Based on the test the market can be segmented into PCR, Immunoassays, and others. By products, the market can be segmented into instruments and consumables. Based on the end-user the market can be segmented into pharmaceutical & biotechnology industries, academic & research institutes, diagnostic centers, and others.


Geographically, host cell contaminant testing market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.


Key Players Covered:


The major companies in the global host cell contaminant testing report Cisbio Bioassays, Cygnus Technologies, Bio-Rad Laboratories, Inc., Enzo Life Sciences Inc., BioGenes, Molecular Devices, LLC., ForteBio, GENERAL ELECTRIC COMPANY, Thermo Fisher Scientific, ProteinSimple., Bio-Techne, BioAgilytix Labs and other prominent players.


Key Insights:



  • Introduction of New Products / Approvals (By Major Players)

  • Key Strategies of Leading Market Players

  • Key Industry Developments - Mergers, Acquisitions and Partnerships

  • Recent Host Cell Contaminant Testing Research & Development Activities


Regional Analysis:


Geographically, the global host cell contaminant testing market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North American region is likely to hold the largest share of the market and is anticipated to follow the same momentum over the forecast period owing to the increasing expenditure in research. The United States is expected to witness the highest growth due to the plethora of biopharmaceutical companies, world-class research universities, and academic medical centers. Moreover, the R&D spending of the U.S. is quite higher than in most of the regions. For instance, in 2014, the U.S. witnessed the most top R&D investments in biotechnology and, since then, the US biotechnology research and investment has been growing at a steady rate. Europe is projected to be the second most productive market throughout the forecast period. The development of new products and partnership activities of pharmaceutical and biotechnology companies is likely to boost the growth of the market in this region. However, Asia-Pacific possesses the high growth opportunity due to an increase in the purchasing power of the countries of this region and R&D expenditure. Investments in the pharmaceutical and biotechnology industry segments are likely to propel the market growth. This fast-growing startup space in the country stimulated by the influx of capital will encourage added research and development efforts toward building advanced technologies.



Segmentation


























 ATTRIBUTE


  DETAILS

By Type




  • Microbial

  • Mammalian

  • Others



By Test




  • PCR

  • Immunoassay

  • Others



By End-Users




  • Pharmaceutical & Biotechnology Industries

  • Academic & Research Institutes

  • Diagnostic Centres

  • Others



By Geography




  • North America (USA, Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico, Rest of Latin America)

  • Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)



Host Cell Contaminant Testing Market Industry Developments



  • In November 2019, Thermo Fisher Scientific announced the launch of its Ion Torrent Genexus System, the first fully integrated, next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that delivers results economically in a single day.

  • In August 2019, Bio-Techne announced its partnership with Cygnus Technologies for the quantification of Chinese hamster ovary host cell proteins (CHO-HCP) on the ProteinSimple branded Ella immunoassay platform.

  • In June 2019, Cygnus Technologies announced an expansion of its service offerings for host cell protein (HCP) impurities detection, identification, and quantification which can impact the efficacy and stability of the therapeutic.

  • Global
  • 2023
  • 2019-2022
  • PRICE
  • $ 4850
    $ 5850
    $ 6850
    Pre Book

Healthcare Clients